Advanced Renal Cell Carcinoma

Evaluating Bempegaldesleukin, Nivolumab as a First-Line Treatment for Patients With ccRCC
Research from Nizar M. Tannir, MD, FACP, and colleagues published in the Journal of Clinical Oncology investigated the safety and efficacy of the pegylated interleukin-2 cytokine prodrug bempegaldesleukin plus nivolumab as a first-line treatment for patients with intermediate- or poor-risk advanced or metastatic clear cell renal cell carcinoma (ccRCC). ...
Advertisement

Latest News

Advertisement

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement
Get the latest RCC research straight to your inbox.